undamentalytics Newsletter
Sign in

Amylyx Pharmaceuticals, Inc. (AMLX) stock

Add to watchlist

Add holding +

NASDAQ: AMLX Nasdaq Biotechnology Next results ~November 5, 2026

Amylyx Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling2 purchases and 31 sales by directors and officers, last 12 monthsInsider trades
  • Funds118 adding, 72 cuttingOf 43 active managers that changed their stake, 26 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Amylyx Pharmaceuticals files

Where Amylyx Pharmaceuticals stands after its latest 10-K

Amylyx Pharmaceuticals has little or no product revenue yet; it used $127m of cash in the twelve months to December 2025. The diluted share count is up 36.5% on a year earlier, which dilutes existing holders.

Our model value for Amylyx Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-K filed March 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Amylyx Pharmaceuticals, Inc.'s trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of 23236.1%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -100.0% (-22.9pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 23660.3% of revenue is left as operating profit.
  • Margins widening. Operating margin is up 23798.8 points on a year ago.
  • Strong cash generation. 23236.1% of revenue turned into free cash flow.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Growth slowing. The growth rate is 22.9 points lower than a quarter earlier.
  • Share dilution. Diluted shares rose 36.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 86% and a beta of 0.9 against the S&P 500.
  • Heavily shorted. 13.2% of the shares available to trade are sold short (9.5 days of average volume to cover).

Latest results: FY2025 Q4

Filed March 3, 2026
Earnings per share
-$0.39 against an average estimate of -$0.36: missed by 9.0%
Share reaction
+4.4% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.37

Amylyx Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week+3.5%
  • 1 month+0.9%
  • This year+132.1%
  • 1 year+101.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
23660.3%
Net margin
22448.4%
EPS (TTM, diluted)
$-1.43

Growth

Revenue growth
−100.0%
Change in growth rate
−22.9 pts
Share count change
+36.5%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Amylyx Pharmaceuticals, Inc. valuation models and calculator

No model value for Amylyx Pharmaceuticals, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $41600 and EPS of −$0.37 (range −$0.42 to −$0.31) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.48 +3% — 0%
Next −$1.09 +27% $28m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.1% on 90 days ago. In the last 30 days, 2 analysts raised Amylyx Pharmaceuticals, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Amylyx Pharmaceuticals, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.43 Current fiscal year, 60 days ago: −$1.50 Current fiscal year, 30 days ago: −$1.50 Current fiscal year, 7 days ago: −$1.48 Current fiscal year, Now: −$1.48 −$1.48 Next fiscal year, 90 days ago: −$1.36 Next fiscal year, 60 days ago: −$1.15 Next fiscal year, 30 days ago: −$1.15 Next fiscal year, 7 days ago: −$1.09 Next fiscal year, Now: −$1.09 −$1.09

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.43−$1.36
60 days ago −$1.50−$1.15
30 days ago −$1.50−$1.15
7 days ago −$1.48−$1.09
Now −$1.48−$1.09

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.36 −$0.39 −9.0%
Mar 2026 −$0.34 −$0.37 −8.7%
Dec 2025 −$0.34 −$0.30 +12.2%
Sept 2025 −$0.43 −$0.37 +13.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202611112
  2. Sep 202611112
  3. Aug 202611112
  4. Jul 202610111

Counts of recommendations published by analysts covering Amylyx Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.2%
of tradable shares
Days to cover
9.49
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
94%
of shares
Held by insiders
7.2%
of shares
Employees
136
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
AMLX−60%−74%+220%+132%
Industry peers (median)−17%−28%−5%−27%
S&P 500+26%+25%+18%+11%
Months that ended higher
AMLX25%67%75%55%
S&P 50067%75%75%46%
Largest fall from a high during the year
AMLX−71%−92%−28%−34%
S&P 500−10%−8%−19%−9%

Worst fall since January 7, 2022: 96% from January 27, 2023 to June 18, 2024. Getting back needed a 2427% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$11.38 – $39.66
From 52-week high
−29.3%
vs 50-day average
−8.6%
vs 200-day average
+39.1%
Volatility (1 year)
87%
Beta vs S&P 500
0.93

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.1%
After a week
5 up, 7 down
typical move ±12.8%
After a month
6 up, 6 down
typical move ±26.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +4.4% +0.5% +2.9% +56.1%
May 7, 2026 −8.3% +0.5% −13.6% −19.0%
March 3, 2026 −1.6% −0.2% −2.1% −6.2%
November 6, 2025 −7.0% −1.0% −6.2% +3.2%
August 7, 2025 −6.7% +0.7% +2.7% +27.5%
May 8, 2025 −5.3% +0.6% −7.2% +11.7%
March 4, 2025 +12.0% −0.1% +24.3% +26.0%
November 7, 2024 +7.7% +1.2% −19.3% −21.5%
August 8, 2024 +1.1% +2.8% +14.9% +34.0%
May 9, 2024 −9.1% +0.7% −5.2% −8.8%
February 22, 2024 +15.3% +2.1% +23.1% −82.1%
November 9, 2023 −30.7% +0.8% −32.6% −20.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Amylyx Pharmaceuticals, Inc.
-$100M $0 $100M $200M $300M $400M FY23 Q2 FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 Revenue (TTM), FY23 Q2: $191.9M Revenue (TTM), FY23 Q3: $294.2M Revenue (TTM), FY23 Q4: $380.8M Revenue (TTM), FY24 Q1: $398M Revenue (TTM), FY24 Q2: $298.8M Revenue (TTM), FY24 Q3: $196.5M Revenue (TTM), FY24 Q4: $87.4M Revenue (TTM), FY25 Q1: -$1.3M Revenue (TTM), FY25 Q2: -$249K Revenue (TTM), FY25 Q3: -$665K Revenue (TTM), FY25 Q4: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY23 Q2 $191.9M
FY23 Q3 $294.2M
FY23 Q4 $380.8M
FY24 Q1 $398M
FY24 Q2 $298.8M
FY24 Q3 $196.5M
FY24 Q4 $87.4M
FY25 Q1 -$1.3M
FY25 Q2 -$249K
FY25 Q3 -$665K
FY25 Q4 $0
Revenue growth, TTM YoY Amylyx Pharmaceuticals, Inc.
-100% -50% 0% 50% 100% FY24 Q2 FY24 Q3 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY24 Q2: 55.7% Revenue growth, TTM YoY, FY24 Q3: -33.2% Revenue growth, TTM YoY, FY24 Q4: -77.1% Revenue growth, TTM YoY, FY25 Q4: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 55.7%
FY24 Q3 -33.2%
FY24 Q4 -77.1%
FY25 Q4 -100.0%
Operating margin (TTM) Amylyx Pharmaceuticals, Inc.
-20000% 0% 20000% 40000% 60000% 80000% FY23 Q2 FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q3 Operating margin (TTM), FY23 Q2: -42.3% Operating margin (TTM), FY23 Q3: -2.6% Operating margin (TTM), FY23 Q4: 10.2% Operating margin (TTM), FY24 Q1: -20.4% Operating margin (TTM), FY24 Q2: -59.5% Operating margin (TTM), FY24 Q3: -138.5% Operating margin (TTM), FY24 Q4: -360.2% Operating margin (TTM), FY25 Q1: 18113.5% Operating margin (TTM), FY25 Q2: 79106.4% Operating margin (TTM), FY25 Q3: 23660.3% 23660.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q2 -42.3%
FY23 Q3 -2.6%
FY23 Q4 10.2%
FY24 Q1 -20.4%
FY24 Q2 -59.5%
FY24 Q3 -138.5%
FY24 Q4 -360.2%
FY25 Q1 18113.5%
FY25 Q2 79106.4%
FY25 Q3 23660.3%
FCF margin (TTM) Amylyx Pharmaceuticals, Inc.
-20000% 0% 20000% 40000% 60000% 80000% FY23 Q2 FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q3 FCF margin (TTM), FY23 Q2: -47.3% FCF margin (TTM), FY23 Q3: -18.0% FCF margin (TTM), FY23 Q4: 2.8% FCF margin (TTM), FY24 Q1: 3.9% FCF margin (TTM), FY24 Q2: -19.9% FCF margin (TTM), FY24 Q3: -48.6% FCF margin (TTM), FY24 Q4: -192.1% FCF margin (TTM), FY25 Q1: 16280.1% FCF margin (TTM), FY25 Q2: 66537.8% FCF margin (TTM), FY25 Q3: 23236.1% 23236.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q2 -47.3%
FY23 Q3 -18.0%
FY23 Q4 2.8%
FY24 Q1 3.9%
FY24 Q2 -19.9%
FY24 Q3 -48.6%
FY24 Q4 -192.1%
FY25 Q1 16280.1%
FY25 Q2 66537.8%
FY25 Q3 23236.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 22 381 87 0
Gross profit — 19 355 81 0
EBITDA −83 −201 40 −314 −153
Operating income −83 −201 39 −315 −153
Net income −88 −198 49 −302 −145
Diluted EPS −$13.35 −$3.39 $0.70 −$4.43 −$1.53
Growth (year on year)
Revenue — +>999% +>999% −77.1% −100.0%
EBITDA — — — −886.7% —
Operating income — — — −911.1% —
Net income — — — −712.4% —
Diluted EPS — — — −732.9% —
Margins
Gross margin — 86.5% 93.3% 93.2% —
EBITDA margin <−999% −903.5% 10.5% −359.2% —
Operating margin <−999% −905.7% 10.2% −360.2% —
Net margin <−999% −892.4% 12.9% −345.4% —
Free-cash-flow margin <−999% −820.5% 2.8% −192.1% —
Cash flow
Cash from operations −75 −180 12 −168 −123
Capital spending 0 3 1 0 0
Free cash flow −75 −182 11 −168 −123
Stock-based pay 3 22 37 33 28
Free cash flow after stock pay −78 −204 −26 −201 −151
Balance sheet
Cash 50 63 170 77 227
Total debt 0 0 0 0 0
Net debt (negative = net cash) −50 −63 −170 −77 −227
Diluted shares 7m 58m 70m 68m 95m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+36.5%
year over year
R&D spending
-13847.1%
of revenue
Sales & admin spending
-9713.2%
of revenue

Who owns it

Funds buying and selling
Reported value
$2.1B
Institutions reporting
206
Shares held vs prior quarter
▲ 0.6%
Positions opened / closed
47 / 13

Top buyers and sellers, Q2 2026: 118 institutions bought and 72 sold ; the biggest buyer was Jpmorgan Chase & Co (+1.7M shares) and the biggest seller Adage Capital Partners Gp, L.L.C (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $300M 16.7M 14.5% ▲ 0.6%
Blackrock, Inc. $159M 8.8M 7.6% 0.0%
Perceptive Advisors LLC $150M 8.3M 7.2% ▲ 0.6%
Tcg Crossover Management, LLC $112M 6.2M 5.4% 0.0%
Commodore Capital LP $101M 5.7M 4.9% 0.0%
Jupiter Topco LLC $94M 5.2M 4.5% —
Saturn V Capital Management LP $83M 4.6M 4.0% ▲ 6.3%
Vanguard Capital Management LLC $75.9M 4.2M 3.7% ▲ 2.0%
Morgan Stanley $56.2M 3.1M 2.7% ▲ 43.9%
Driehaus Capital Management LLC $54.5M 3.0M 2.6% ▲ 1.7%
First Light Asset Management, LLC $54.3M 3.0M 2.6% ▼ 5.2%
Franklin Resources Inc $53M 3.0M 2.6% ▲ 30.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Amylyx Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $152,183 2 trades by 1 insider, last 12 months Insider sales History → $10.1M 31 trades by 6 insiders · 14% under pre-set plans
Net ▼ $10M net selling
Insider Date Trade Shares Price Value
Milne George M Jr Director October 5, 2026 Sell pre-set plan 30,000 $27.70 $830,904
Klee Justin B. Co-Chief Executive Officer September 10, 2026 Sell 29,025 $32.13 $932,573
Klee Justin B. Co-Chief Executive Officer September 10, 2026 Sell 1,439 $33.16 $47,717
Cohen Joshua B Co-Chief Executive Officer September 10, 2026 Sell 29,545 $32.16 $950,167
Cohen Joshua B Co-Chief Executive Officer September 10, 2026 Sell 919 $33.15 $30,465
Mazzariello Gina Chief Legal Officer September 10, 2026 Sell 11 $33.34 $367
Mazzariello Gina Chief Legal Officer September 10, 2026 Sell 9,525 $32.46 $309,182
Frates James M Chief Financial Officer September 10, 2026 Sell 1,042 $33.23 $34,626
Frates James M Chief Financial Officer September 10, 2026 Sell 9,768 $32.27 $315,213
Bedrosian Camille L Chief Medical Officer September 10, 2026 Sell 2,081 $33.09 $68,860
Bedrosian Camille L Chief Medical Officer September 10, 2026 Sell 7,947 $32.21 $255,973
Mazzariello Gina Chief Legal Officer July 10, 2026 Sell pre-set plan 15,000 $17.61 $264,150

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Amylyx Pharmaceuticals, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Chris Jacobs(R-NY 27):Purchase, $1,001 - $15,000, traded October 12, 2022, filed November 16, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 3, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Amylyx Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Amylyx Pharmaceuticals, Inc. in brief

What does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Amylyx Pharmaceuticals, Inc.'s stock ticker?
Amylyx Pharmaceuticals, Inc. trades under the ticker AMLX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Amylyx Pharmaceuticals, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Amylyx Pharmaceuticals, Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Amylyx Pharmaceuticals, Inc.'s free cash flow?
Amylyx Pharmaceuticals, Inc.'s free-cash-flow margin is 23236.1% of revenue over the trailing twelve months.
Who are Amylyx Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Perceptive Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Amylyx Pharmaceuticals, Inc.'s market cap?
On December 31, 2025, Amylyx Pharmaceuticals, Inc.'s market capitalisation was about $1.1B and net debt of -$227M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Amylyx Pharmaceuticals, Inc. stock?
Over the last 12 months, Amylyx Pharmaceuticals, Inc.'s directors and officers reported 2 open-market purchases and 31 sales on Form 4. The insider trading page charts every trade.
When is Amylyx Pharmaceuticals, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Amylyx Pharmaceuticals, Inc. announces its own schedule.